Blood Test for Lung Cancer

The test has received the CE Mark and will be marketed in Europe under the brand name CellCorrect KvA-40 lab kit.

The new test is an inexpensive way to detect altered autoimmunity and associated patterns of disease-related autoantibodies in the bloodstream that are produced by the immune system, according to the test's developer, CeMines, Inc. (Golden, CO, USA). CeMines calls its technology Molecular FingerPrinting.

The company has conducted international patient studies that demonstrated consistent patterns of specific biomarkers that have proven their utility as viable composite biomarkers able to differentiate and characterize cancer. CeMines uses a patent-pending bioinformatics application for biomarker analysis, followed by specific pattern-recognition algorithms. The data are presented in an easy-to-read score that does not require subjective interpretation by doctors.

"We believe that our integration of the CellCorrect diagnostic array protocol and CeMines molecular Finger-Printing bioinformatics applications will eventually establish the CellCorrect product family as the most cost-effective and operationally efficient DX modality available today,” stated Roger Attick, president and CEO of CeMines.




Related Links:
CeMines